Anticoagulant Therapy

Heparin Therapeutc Range

From Keith DeHaas, Southwestern Vermont Healthcare: Hi George I am currently enrolled in BLD 835 and am thoroughly enjoying the class. I have a question about sourcing specimens of plasma with unfractionated heparin for use in ex vivo Xa studies. We are a small hospital that does not use much heparin and getting enough heparinized […]

Anticoagulant Therapy

Anti-Xa Nomenclature

FF Participants, the PTT versus Anti-Xa entry has morphed into a discussion of anti-Xa nomenclature, so I’ve decided to start a new thread. Be sure to link back to the prior thread to see where this is coming from. From Dr. Favaloro: Couldn’t resist adding my support to this. We have moved away from “anti-Xa” […]

Anticoagulant Therapy

Idarucizumab for Dabigatran Reversal

Some recent news about dabigatran reversal, a report on the REVERSE-AD study, is reported in The Heart.Org.

Anticoagulant Therapy

PTT Versus Anti-Xa

For several years, most coagulation specialists have supported using the chromogenic anti-Xa assay in place of the PTT for monitoring unfractionated heparin therapy. We contend the anti-Xa is more accurate and reproducible as it is less prone to interference. Many medical center laboratories have converted to the anti-Xa as their primary means for monitoring UFH, […]

Anticoagulant Therapy

Lovenox Causes Urinary Tract Bleeding

George received this message from Prof. Emerita Bernadette (Bunny) Rodak, editor and author of Rodak’s Hematology: Clinical Principles and Applications. Bunny has an ovarian tumor accompanied by some clotted abdominal vessels, and has been receiving 120 mg of Lovenox once a day. She has experienced bleeding after each dosage and had asked whether she could […]

Anticoagulant Therapy

Stable Dabigatran Levels in Anticoagulation Clinic Patieents

This abstract was presented as a poster at the American Society for Clinical Laboratory Science annual meeting, Atlanta, July, 2015: McGlasson DL, Fritsma GA. Stable Dabigatran Levels in Anticoagulation Clinic Patients: An Unexpected Finding. Clin Lab Sci 2015; 28:159. The dabigatran effect is rapid. Its half-life is 12–17 hours. Experts believe missed doses may lead […]

Anticoagulant Therapy

Blood Coagulation and Fibrinolysis Publication

Announcing our latest publication, McGlasson DL, Fritsma GA. Measuring dabigatran with the dilute Russell viper venom confirm assay in an anticoagulation clinic population. Blood Coagul Fibrinolysis. 2015 Aug 7. [Epub ahead of print].

Anticoagulant Therapy

Rivaroxaban in Diabetes

Here is a current Heartwire announcement about the use of Rivaroxaban in diabetics. The data for this outcome is derived from the ROCKET-AF study.

Anticoagulant Therapy

Idarucizumab for Dabigatran Reversal

Melissa Thomas at Boehringer Ingelheim sent a press release about the report of their phase III trial, Idarucizumab for Dabigatran Reversal. The free full text article, Pollack CV, Reliiy PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal, NEJM 2015, DOI: 10.1056/NEJMoa1502000, is available from the NEJM web site.

Anticoagulant Therapy

Dabigatran Reversal Agent

In a report given at the International Society for Thrombosis and Haemostasis biennial meeting in Toronto, Dr. Charles Pollack indicated that a trial of the Boehringer-Ingelheim drug idarucizumab safely and effectively reversed the effects of dabigatran. To see the full report, select Dabigatran Reversal Agent RE-VERSE AD on Heartwire.

Anticoagulant Therapy

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question